A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting

Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting - Light Version

The main purpose of this study to investigate the relationship between clinical symptoms and quality of life (QoL) in participants who receive Tildrakizumab in the frame of clinical routine for the treatment of moderate to severe plaque psoriasis in accordance with the summary of product characteristics (SmPC).

Inclusion Criteria:

• Participant with diagnosis of moderate or severe chronic plaque PSO documented in the medical chart.
• Participant who needs systemic biologic therapy and qualifies for treatment with an IL-23p19 inhibitor. Tildrakizumab must be the anti-Il-23p19 selected therapy before including the patient in the study.
• Participant aged greater than or equal to (>=) 18 years at Inclusion.
• Written informed consent.

Exclusion Criteria:

• Participant unable or unwilling to comply with the requirements of the study.
• Participant who should not participate in the study for any reason at the discretion of the treating physician.
• Participants participating in a simultaneous clinical trial.
• Any contraindication against the use of Tildrakizumab according to the SmPC.
• Exposure to >= 3 biologics prior to inclusion.
• Participant dependent on the investigator, e.g. as employee